Mirum Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) on August 24, 2023. The report details amendments to the Company's Severance Benefit Plan approved by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements and does not contain financial performance data.
Material Changes
The primary material change is the amendment and restatement of the Severance Benefit Plan. Key modifications include:
- Removal of the automatic "sunset" provision for the Severance Plan.
- Implementation of specific administrative changes to the plan.
- Modification of severance benefits for Named Executive Officers (NEOs), including Christopher Peetz, Lara Longpre, Peter Radovich, and Pamela Vig.
Outlook, Risks, and Unusual Items
The Company expects to enter into new participation agreements with the affected executive officers to reflect the modified benefits. The filing outlines specific severance entitlements based on termination scenarios:
- Outside Change in Control Period:
- Christopher Peetz: 12 months base salary, 12 months accelerated equity vesting, 12 months healthcare.
- Other NEOs: 9 months base salary, 12 months accelerated equity vesting, 9 months healthcare.
- During Change in Control Period:
- Christopher Peetz: 24 months base salary, 200% target bonus, full equity acceleration, 24 months healthcare.
- Other NEOs: 18 months base salary, 150% target bonus, full equity acceleration, 18 months healthcare.
Investor Verification Checklist
- Verify the specific terms of the new participation agreements to be executed with Christopher Peetz, Lara Longpre, Peter Radovich, and Pamela Vig.
- Review the full text of the Amended and Restated Severance Benefit Plan (Exhibit 10.1) for detailed definitions of "cause," "good reason," and "change in control period."
- Assess the potential financial impact of the increased severance liabilities, particularly the 200% and 150% bonus provisions triggered by a change in control.
- Confirm the removal of the sunset provision ensures the plan remains in effect indefinitely unless further amended.